Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dynamic Susceptibility Contrast-Enhanced MR Perfusion Imaging in Assessing Recurrent Glioblastoma Response to Superselective Intra-Arterial Bevacizumab Therapy.
Singh R, Kesavabhotla K, Kishore SA, Zhou Z, Tsiouris AJ, Filippi CG, Boockvar JA, Kovanlikaya I. Singh R, et al. Among authors: kesavabhotla k. AJNR Am J Neuroradiol. 2016 Oct;37(10):1838-1843. doi: 10.3174/ajnr.A4823. Epub 2016 May 26. AJNR Am J Neuroradiol. 2016. PMID: 27231225 Free PMC article.
Metabolic response of glioblastoma to superselective intra-arterial cerebral infusion of bevacizumab: a proton MR spectroscopic imaging study.
Jeon JY, Kovanlikaya I, Boockvar JA, Mao X, Shin B, K Burkhardt J, Kesavabhotla K, Christos P, Riina H, Shungu DC, Tsiouris AJ. Jeon JY, et al. Among authors: k burkhardt j, kesavabhotla k. AJNR Am J Neuroradiol. 2012 Dec;33(11):2095-102. doi: 10.3174/ajnr.A3091. Epub 2012 May 10. AJNR Am J Neuroradiol. 2012. PMID: 22576886 Free PMC article. Clinical Trial.
Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article.
Boockvar JA, Tsiouris AJ, Hofstetter CP, Kovanlikaya I, Fralin S, Kesavabhotla K, Seedial SM, Pannullo SC, Schwartz TH, Stieg P, Zimmerman RD, Knopman J, Scheff RJ, Christos P, Vallabhajosula S, Riina HA. Boockvar JA, et al. Among authors: kesavabhotla k. J Neurosurg. 2011 Mar;114(3):624-32. doi: 10.3171/2010.9.JNS101223. Epub 2010 Oct 22. J Neurosurg. 2011. PMID: 20964595 Free PMC article. Clinical Trial.
Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival.
Burkhardt JK, Riina H, Shin BJ, Christos P, Kesavabhotla K, Hofstetter CP, Tsiouris AJ, Boockvar JA. Burkhardt JK, et al. Among authors: kesavabhotla k. World Neurosurg. 2012 Jan;77(1):130-4. doi: 10.1016/j.wneu.2011.05.056. Epub 2011 Nov 21. World Neurosurg. 2012. PMID: 22405392 Free PMC article. Clinical Trial.
Glioblastoma stem-like cells-biology and therapeutic implications.
Gürsel DB, Shin BJ, Burkhardt JK, Kesavabhotla K, Schlaff CD, Boockvar JA. Gürsel DB, et al. Among authors: kesavabhotla k. Cancers (Basel). 2011 Jun 10;3(2):2655-66. doi: 10.3390/cancers3022655. Cancers (Basel). 2011. PMID: 21796273 Free PMC article.
Industry progress report on neuro-oncology: a biotech update.
Haber JS, Banu MA, Ray A, Kesavabhotla K, Boockvar JA. Haber JS, et al. Among authors: kesavabhotla k. J Neurooncol. 2013 Apr;112(2):315-21. doi: 10.1007/s11060-012-1036-8. Epub 2013 Feb 20. J Neurooncol. 2013. PMID: 23423513
48 results